AUS
NZ
UK
CA
USA
IND
ResMed (ASX: RMD) witnesses a remarkable upswing in its ASX-listed shares, soaring by as much as 8.91% to AU$31.30 apiece, poised to register its most exceptional performance since October 30, 2020, should the gains hold. The surge catapults ResMed into the upper echelons of top gainers within the benchmark index, underscoring the market's bullish sentiment towards the medical device company.
A stellar quarterly performance propels ResMed's shares to newfound heights, buoyed by robust demand for its sleep apnea devices. The company eclipses Wall Street estimates for quarterly profit, reporting an adjusted profit of AU$2.13 per share for the quarter ending 31 March, surpassing market consensus of AU$1.94 per share, as reported by Citi. This impressive feat underscores ResMed's resilience and market prowess in meeting and exceeding investor expectations.
In addition to surpassing profit expectations, ResMed reports a substantial uptick in quarterly sales, with revenues climbing by 7% to reach AU$1.2 billion. This robust revenue growth further bolsters investor confidence in ResMed's business fundamentals and its ability to capitalise on burgeoning market opportunities.
The buoyancy in ResMed's shares is further accentuated by their ascent to the highest levels since August 3, marking a fifth consecutive day of gains. This sustained upward trajectory underscores investor optimism and underscores ResMed's status as a standout performer in the market landscape.
As of the last close, ResMed shares have surged by approximately 13% year-to-date, underscoring the company's strong momentum and investor appeal. The steady appreciation in ResMed's stock price reflects the market's recognition of the company's solid performance and its potential for sustained growth in the foreseeable future.
Against the backdrop of a challenging economic landscape, ResMed's stellar quarterly performance serves as a testament to its resilience and ability to thrive in adverse market conditions. The company's unwavering focus on innovation, coupled with its robust financial performance, positions it as a formidable player in the medical device industry, poised for continued success and value creation for its shareholders.
